Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Gene Rank description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 752 to 801 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
752\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LIPOPOLYSACCHARIDE-RESPONSIVE AND BEIGE-LIKE ANCHOR PROTEIN (CDC4-LIKE PROTEIN) (BEIGE-LIKE PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0321572\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.121579\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.264496336\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
753\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LUPUS LA PROTEIN (SJOGREN SYNDROME TYPE B ANTIGEN) (SS-B) (LA RIBONUCLEOPROTEIN) (LA AUTOANTIGEN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.302351\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.14316\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.264487036\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SSB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
754\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
U4/U6-ASSOCIATED RNA SPLICING FACTOR. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.351386\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.32896\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.264406754\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRPF3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
755\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0328701\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.124442\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.264139921\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CCDC93\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
756\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5 (APOPTOSIS INHIBITOR SURVIVIN) (APOPTOSIS INHIBITOR 4). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.168097\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.636394\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.264139825\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BIRC5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
757\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FAS APOPTOTIC INHIBITORY MOLECULE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.118199\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.447876\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.2639101\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FAIM\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
758\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
43 KDA RECEPTOR-ASSOCIATED PROTEIN OF THE SYNAPSE (RAPSYN) (ACETYLCHOLINE RECEPTOR-ASSOCIATED 43 KDA PROTEIN) (43 KDA POSTSYNAPTIC PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.552551\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.09375\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263904955\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAPSN\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
759\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
C1 DOMAIN-CONTAINING PHOSPHATASE AND TENSIN-LIKE PROTEIN ISOFORM 2; PUTATIVE PROTEIN TYROSINE PHOSPHATASE; C1 DOMAIN-CONTAINING PHOSPHATASE AND TENSIN-LIKE PROTEIN; TENSIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.260485\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.987283\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263840257\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TENC1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
760\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TUMOR ENDOTHELIAL MARKER 6; THYROID SPECIFIC PTB DOMAIN PROTEIN; TENSIN 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.283226\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.0738\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263760477\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TNS3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
761\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SEGMENT POLARITY PROTEIN DISHEVELLED HOMOLOG DVL-1 (DISHEVELLED-1) (DSH HOMOLOG 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.217793\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.825859\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.26371693\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DVL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
762\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SEGMENT POLARITY PROTEIN DISHEVELLED HOMOLOG DVL-2 (DISHEVELLED-2) (DSH HOMOLOG 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.223153\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.846393\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263651755\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DVL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
763\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAB COUPLING PROTEIN; RAB-INTERACTING RECYCLING PROTEIN; RAB EFFECTOR PROTEIN; RAB11-FAMILY INTERACTING PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0360283\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.136657\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263640355\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAB11FIP1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
764\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POTENTIAL PHOSPHOLIPID-TRANSPORTING ATPASE IIA (EC 3.6.1.-). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0460867\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.174809\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.263640316\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATP9A\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
765\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GAMMA-SNAP-ASSOCIATED FACTOR 1; RAB11-INTERACTING PROTEIN. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
RAB11FIP5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
766\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN C14ORF122 (CGI-112). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0365698\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.138711\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.26364023\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C14orf122\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
767\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0355674\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.134909\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263639935\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAB11FIP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
768\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DPY-30-LIKE PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.3486\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.32226\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263639526\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
769\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEIGHBOR OF COX4. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0269837\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.102351\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263638851\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
COX4NB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
770\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HSP90 CO-CHAPERONE CDC37 (HSP90 CHAPERONE PROTEIN KINASE-TARGETING SUBUNIT) (P50CDC37). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.188365\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.715239\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.26335952\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CDC37\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
771\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SEGMENT POLARITY PROTEIN DISHEVELLED HOMOLOG DVL-3 (DISHEVELLED-3) (DSH HOMOLOG 3). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.256243\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.973151\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263312682\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DVL3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
772\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CASEIN KINASE II BETA CHAIN (CK II) (PHOSVITIN) (G5A). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.492676\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.87133\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263275852\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
773\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SIRTUIN 7; SIR2-RELATED PROTEIN TYPE 7; SIRTUIN TYPE 7; SIRTUIN (SILENT MATING TYPE INFORMATION REGULATION 2, S.CEREVISIAE, HOMOLOG) 7; SILENT MATING TYPE INFORMATION REGULATION 2, S.CEREVISIAE, HOMOLOG 7; SIRTUIN SILENT MATING TYPE INFORMATION REGULATION"\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0367538\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.139602\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263275598\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
774\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TARGET OF MYB1-LIKE 2; TARGET OF MYB1 (CHICKEN) HOMOLOG-LIKE 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.179057\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.680239\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263226601\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TOM1L2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
775\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRIPLE FUNCTIONAL DOMAIN PROTEIN (PTPRF INTERACTING PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0734189\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.278919\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.2632266\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TRIO\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
776\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TARGET OF MYB PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.230424\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.875383\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263226496\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TOM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
777\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HUNTINGTIN-ASSOCIATED PROTEIN-INTERACTING PROTEIN (DUO PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0568574\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.216002\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263226266\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
778\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARP2/3 COMPLEX 34 KDA SUBUNIT (P34-ARC) (ACTIN-RELATED PROTEIN 2/3 COMPLEX SUBUNIT 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.427564\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.62441\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263211874\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARPC2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
779\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TENSIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.320357\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.21727\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263176617\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TNS1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
780\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RNA-BINDING REGION CONTAINING PROTEIN 2 (HEPATOCELLULAR CARCINOMA PROTEIN 1) (SPLICING FACTOR HCC1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.349158\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.32674\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263169875\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBM39\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
781\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"NUCLEAR FACTOR, INTERLEUKIN 3 REGULATED. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.150787\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.573002\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263152659\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFIL3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
782\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNTAXIN 12. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.206261\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.78389\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.263124928\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
STX12\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
783\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WW DOMAIN BINDING PROTEIN 2 (WBP-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0979343\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.372839\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262671823\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WBP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
784\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0378601\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.144194\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.26256363\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
785\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.11358\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.432583\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262562329\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BRCA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
786\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNTAXIN 7. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.209282\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.797115\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262549318\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
STX7\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
787\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CBF1 INTERACTING COREPRESSOR. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.363013\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.38457\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262184649\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
788\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EVOLUTIONARILY CONSERVED G-PATCH DOMAIN CONTAINING. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0369504\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.140933\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262184158\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GPATCH1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
789\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADENOVIRUS 5 E1A-BINDING PROTEIN (BS69 PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0552487\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.210853\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262024728\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ZMYND11\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
790\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNTAXIN 16 (SYN16). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.279039\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.06498\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262013371\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
STX16\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
791\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNTAXIN 1A (NEURON-SPECIFIC ANTIGEN HPC-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.147338\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.562331\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262012943\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
STX1A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
792\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0377474\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.144067\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262012813\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TMCC2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
793\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"BETA-SOLUBLE NSF ATTACHMENT PROTEIN (SNAP-BETA) (N-ETHYLMALEIMIDE- SENSITIVE FACTOR ATTACHMENT PROTEIN, BETA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.129493\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.494224\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262012772\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NAPB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
794\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
INFLAMMATION-RELATED G PROTEIN-COUPLED RECEPTOR EX33. \vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0690966\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.263715\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.2620124\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
GPR84\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
795\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PALMITOYL-PROTEIN THIOESTERASE 1 PRECURSOR (EC 3.1.2.22) (PALMITOYL- PROTEIN HYDROLASE 1). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
PPT1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
796\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SIMILAR TO NUCLEAR PROTEIN E3-3 ORF1. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
C3orf60\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
797\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADIPOCYTE PLASMA MEMBRANE-ASSOCIATED PROTEIN (BSCV PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0870266\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.332147\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262012302\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C20orf3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
798\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0312832\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.119396\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262012128\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TMCC3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
799\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNAPTOSOMAL-ASSOCIATED PROTEIN 29 (SNAP-29) (VESICLE-MEMBRANE FUSION PROTEIN SNAP-29) (SOLUBLE 29 KDA NSF ATTACHMENT PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.14026\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.535319\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262011997\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SNAP29\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
800\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNTAXIN 1B. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.120499\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.459899\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262011877\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
STX1B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
801\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA-BINDING PROTEIN RFXANK (REGULATORY FACTOR X SUBUNIT B) (RFX-B) (ANKYRIN REPEAT FAMILY A PROTEIN 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.182131\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.695125\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.262011868\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RFXANK\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/